What You Actually Lose on a GLP-1

GLP-1 medications produce real weight loss, but not all of that weight is fat. Here's what the trial data says about muscle loss, what it means for strength, and what actually helps.

GLP-1 medications like semaglutide and tirzepatide produce weight loss that older interventions couldn't match. What gets left out of most conversations about them is that not all of the weight coming off is fat. Some of it is muscle, and the research on how much, and what to do about it, is more specific than most marketing acknowledges.

What the trials actually measured

In the STEP 1 trial, one of the pivotal semaglutide studies, a substudy used DXA scans, a precise method for measuring body composition, on 140 participants. Over the course of the trial, lean mass fell by 9.7 percent while fat mass fell by 19.3 percent. Fat loss was still the larger share of what came off, but lean mass loss was not trivial.

A broader picture comes from a meta-analysis published in the International Journal of Obesity in June 2026, pooling seven randomized controlled trials and 821 patients on GLP-1 medications. Lean mass fell by an average of 1.74 kilograms, representing somewhere between 14 and 45 percent of total weight lost, depending on the trial. The authors were direct about a limitation worth repeating here: their findings "may not generalize to... older patients," since most of the underlying trials skewed younger than the population increasingly prescribed these drugs, including women managing weight through and after the menopause transition.

Why this matters more, not less, during midlife

Muscle loss carries a different cost for a woman in her 40s or 50s than it does for a 25 year old. Muscle mass is already declining gradually through midlife, and it's one of the more modifiable levers for long term strength, mobility, and metabolic health, a topic our companion piece on strength training in midlife covers directly. Losing a meaningful share of that muscle quickly, as part of rapid medication driven weight loss, isn't automatically dangerous, but it's not nothing either, and it's worth planning around rather than discovering after the fact.

A more encouraging data point, with a real caveat

Not every finding here is discouraging. The SEMALEAN study, published in October 2025 with 106 participants, found that grip strength, a common proxy for overall muscle function, actually increased by 4.5 kilograms on average during GLP-1 treatment, despite the accompanying lean mass loss. The prevalence of sarcopenic obesity, a combination of low muscle mass and excess body fat, fell from 49 percent to 33 percent in the same study.

Taken together with the lean mass data above, the honest picture is that some muscle is being lost, but function isn't necessarily declining in lockstep, at least in this study population. It's a genuinely useful, if incomplete, counterpoint to a purely alarmed reading of the composition data.

A "don't worry about it" viewpoint worth reading carefully

A widely circulated Viewpoint published in JAMA in June 2024 argued that concerns about GLP-1 related muscle loss are overstated. It's a reasonable perspective to be aware of, and it's also worth knowing who wrote it: the authors disclose financial relationships with Eli Lilly and Novo Nordisk, the manufacturers of tirzepatide and semaglutide, respectively, including advisory roles. That doesn't make the argument wrong. It does mean it's coming from people with a financial relationship to the drugs in question, which is exactly the kind of detail this site believes is worth knowing before weighing a claim, the same way industry ties are worth knowing in any other area of health research.

The protein gap nobody is closing

If muscle preservation during GLP-1 treatment depends partly on adequate protein intake, and pairing it with resistance training, the real world data on whether that's happening is not encouraging. One dataset found that only 43 percent of GLP-1 users hit a protein target of 1.2 grams per kilogram of body weight, with the average intake landing at just 77.3 grams per day. Compounding the gap further, no randomized trial has directly tested whether protein supplementation actually preserves muscle during GLP-1 treatment. As the research stands, "direct randomized evidence on protein supplementation during GLP-1 therapy remains absent." People are being told to eat more protein while on these medications, largely on the logic of what helps in other contexts, not because a trial has confirmed it works here specifically.

What this means practically

The appetite suppression that makes GLP-1 medications effective also makes it harder to eat enough protein, at exactly the point where protein intake may matter more. Pairing treatment with resistance training has the strongest, most direct rationale in the muscle preservation literature generally, even though GLP-1 specific trials on this combination are still limited. If you're on one of these medications, that combination, deliberate protein intake and resistance training, is the most evidence aligned response available right now, even though neither has been proven in a dedicated GLP-1 trial to definitively prevent the lean mass loss these drugs produce.

Want a quick starting point?

If you're weighing a GLP-1 medication or already on one and want to think through how to protect muscle and strength along the way, our Find Your Care quiz can help point you toward the right next conversation with a clinician.

Frequently asked questions

Should I be worried about the muscle loss shown in these trials?
It's worth taking seriously rather than ignoring, but the SEMALEAN data suggests function doesn't necessarily decline at the same rate as lean mass. The more useful response is proactive: prioritize protein and resistance training rather than assuming either outcome is inevitable.

Does this mean GLP-1 medications aren't a good option for women in midlife?
No. This article is about what the composition of the weight loss looks like, not whether the medications are worth using. That's a decision that depends on your individual health picture and is worth discussing directly with a clinician.

How much protein should I actually be eating on a GLP-1?
There's no GLP-1 specific trial establishing a confirmed target, so most guidance borrows from general muscle preservation research. What the data does show clearly is that most people on these medications are falling well short of even standard targets, which is worth addressing regardless of the exact number.

Is resistance training actually necessary, or is diet enough?
No randomized trial has isolated this question specifically for GLP-1 users, but in the broader muscle preservation literature, protein without resistance training consistently shows little to no benefit for preserving lean mass. Pairing both has the stronger rationale.

The bottom line

GLP-1 medications produce substantial weight loss, and a meaningful share of it, by some estimates as much as a third or more, is lean mass rather than fat. The research on how to fully prevent that is still incomplete, particularly for women past their 40s, who are underrepresented in the trials this data comes from. What the evidence does support is that pairing treatment with adequate protein and resistance training gives you the best available shot at preserving strength and function while the weight comes off, even without a dedicated trial proving the combination works in this specific context yet.

This article is for general education and is not medical advice.

Sources

‹ What Happens When You Stop

Soy, Flaxseed, and the Truth About Phytoestrogens ›